ProPhase Labs, Inc.

What they do

ProPhase Labs develops and commercializes novel drugs, dietary supplements and compounds through ProPhase BioPharma (PBIO), and offers whole genome sequencing through Nebula Genomics and DNA Complete. It also owns exclusive rights to the BE-Smart esophageal pre-cancer diagnostic screening test, which remains under development and is planned for commercialization as a Laboratory Developed Test. Its former COVID-19 diagnostic testing subsidiaries, ProPhase Diagnostics, Inc. and related entities, ceased testing and filed Chapter 11 in September 2025. The company also sells dietary supplements under the TK Supplements brand.

Revenue drivers

• Genomics (Nebula and DNA Complete) — Whole genome sequencing and related services sold direct-to-consumer online through DNA Complete, formed September 2024, with plans to expand into food, drug and mass retail and university research testing.
• TK Supplements — Dietary supplements including Legendz XL, a male sexual enhancement product, and Triple Edge XL, an energy and stamina support product.
• PBIO drug and supplement pipeline — Licensed compounds including Equivir (an OTC dietary supplement candidate), Equivir G (a prescription antiviral candidate) and Linebacker LB-1 and LB-2 PIM kinase inhibitors; no commercial revenue disclosed.
• BE-Smart esophageal cancer test — Not yet commercialized; the company estimates a potential reimbursement rate of $1,000 to $2,000 per test and an addressable market of $7 billion to $14 billion per year.

Recent performance

Annual revenue fell from $122.6M in 2022 to $35.0M in 2023, $6.8M in 2024 and $4.3M in 2025, as COVID-19 testing wound down. Quarterly revenue most recently was $1.2M for the quarter ended 2026-03-31 and $1.0M for the quarter ended 2026-06-30. Net losses were $16.8M in 2023, $53.4M in 2024 and $14.7M in 2025, with operating cash use of $8.3M in 2025. At 2026-06-30 the company reported total assets of $57.4M, total liabilities of $60.5M and shareholder equity of negative $3.1M, with only $20,000 in cash and equivalents.

Strategy

Management describes ProPhase as a growth-oriented biotech, genomics and consumer products company focused on licensing, developing and commercializing novel drugs, dietary supplements, compounds and diagnostics. The company is pursuing reorganization of the Debtors under Chapter 11, seeking to restore solvency through collection of accounts receivable and eventual operational reorganization of the CLIA-certified laboratory infrastructure. It is taking steps to grow its genomics businesses while continuing to explore a potential sale of Nebula. BE-Smart development continues with a stated plan to commercialize as a Laboratory Developed Test, and PBIO holds licensed antiviral and PIM kinase inhibitor compounds.

Risks

• Severe liquidity constraint — The company held only $20,000 in cash and equivalents at 2026-06-30 while reporting total liabilities of $60.5M and negative shareholder equity of $3.1M.
• Diagnostics subsidiaries in Chapter 11 — ProPhase Diagnostics, Inc. and two indirectly wholly-owned subsidiaries filed voluntary Chapter 11 petitions on September 22, 2025 and were deconsolidated from the consolidated financial statements.
• BE-Smart still unapproved and uncommercialized — The BE-Smart test remains under development, requires further clinical testing, and the company's revenue and market-size estimates depend on reimbursement levels and adoption that have not been achieved.
• Revenue decline and recurring losses — Revenue fell to $4.3M in 2025 from $122.6M in 2022, with net losses in each of 2023, 2024 and 2025 and operating cash use of $8.3M in 2025.

Outlook

Management states the Debtors are pursuing reorganization under Chapter 11 with the objective of restoring solvency through collection of accounts receivable and operational reorganization of the laboratory infrastructure to support additional diagnostic and testing opportunities once the cases progress and resources permit. The company says it is taking steps to grow its genomics businesses while continuing to explore a potential sale of Nebula. It plans to commercialize the BE-Smart test as a Laboratory Developed Test, subject to further development and validation. Debtor plan development is ongoing and any plan will be subject to Bankruptcy Court approval.